EUVIMEDEUVIMED entdecken
Leitlinie

Selecting High-Risk Patients With Pediatric Crohn’s Disease for Top-Down Anti-TNF as per the 2021 ECCO-ESPGHAN Guidelines: A 5-Year Nationwide Retrospective Analysis From Scotland (2016-2020)

Gregor Scott, David I F Wands iD, David C Wilson, Richard Hansen iD, Iain Chalmers iD

Inflammatory Bowel Diseases · 01.08.2025 · 31 (8) · 2059-2065

DOI: 10.1093/ibd/izae298 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 13.12.2024. Verfasst von Gregor Scott und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, UK. Hauptthemen laut MEDLINE: Crohn Disease, Practice Guidelines as Topic, Patient Selection, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Edinburgh Children's Hospital Charity, Edinburgh Children’s Hospital Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2021 ECCO-ESPGHAN guideline on the medical management of pediatric Crohn’s disease promotes early risk stratification and top-down anti-TNF for patients deemed high risk of severe disease course.

Aims

We aimed to objectively assess the risk-benefit profile of the guideline’s risk stratification policy and guidance on top-down anti-TNF in a nationwide population-based cohort study.

Methods

Using a prospectively identified nationwide cohort of all new pediatric patients (<17 years) diagnosed with Crohn’s disease in Scotland between January 1, 2016 and December 31, 2020 and retrospectively applying the current management algorithm, we explored the guideline’s ability to accurately risk stratify patients. Phenotypic and treatment data were retrospectively collected from electronic medical records with a maximum follow-up of 18 months post-diagnosis.

Results

Four hundred and eighteen children (258/418 [62%] male; median [interquartile range {IQR}] age at diagnosis: 13.2 [11.2-14.8] years) were included. High-risk phenotype was present in 224/418 (54%) with 53/224 (24%) of high-risk patients not requiring anti-TNF therapy within 18 months of diagnosis. Conversely, 78/194 (40%) of the low-risk group received anti-TNF within 18 months. High-risk patients were more likely to require anti-TNF (171/224 [76%] vs 78/194 [40%], P < .001) and had shorter median (IQR) time to anti-TNF start (5.0 [1.0-8.0] months vs 6.5 [3.3-13.0] months, P = .01).

Conclusions

Our data support the guideline’s ability to identify patients more likely to require early treatment escalation. However, this approach would have led to potential over- and under-treatment in a substantial proportion of patients. This underscores the importance of frequent and comprehensive monitoring, along with flexible treatment strategies that adapt to changes in disease status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseasePractice Guidelines as TopicPatient SelectionTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaHumansMaleFemaleRetrospective StudiesScotlandAdolescentChildRisk AssessmentFollow-Up Studies

Stichwörter der Autor:innen

Crohn’s diseaseanti-TNFpediatric

Substanzen

Tumor Necrosis Factor InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, UK.
  • Child Life and Health, Centre for Inflammation Research, University of Edinburgh, Royal Hospital for Children & Young People, Edinburgh, UK.
  • Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, UK.
  • Department of Child Health, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK.
  • Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Aberdeen Children's Hospital, Aberdeen, UK.

ORCID-Profile: David I F Wands, Richard Hansen, Iain Chalmers

Förderung

  • Edinburgh Children's Hospital Charity
  • Edinburgh Children’s Hospital Charity

Zitieren

APA

Scott, G., Wands, D. I. F., Wilson, D. C., Hansen, R., & Chalmers, I. (2025). Selecting High-Risk Patients With Pediatric Crohn’s Disease for Top-Down Anti-TNF as per the 2021 ECCO-ESPGHAN Guidelines: A 5-Year Nationwide Retrospective Analysis From Scotland (2016-2020). Inflammatory Bowel Diseases, 31(8), 2059-2065. https://doi.org/10.1093/ibd/izae298

Vancouver

Scott G, Wands DIF, Wilson DC, Hansen R, Chalmers I. Selecting High-Risk Patients With Pediatric Crohn’s Disease for Top-Down Anti-TNF as per the 2021 ECCO-ESPGHAN Guidelines: A 5-Year Nationwide Retrospective Analysis From Scotland (2016-2020). Inflammatory Bowel Diseases. 2025;31(8):2059-2065. doi:10.1093/ibd/izae298

BibTeX
@article{Scott2025,
  author = {Scott, Gregor and Wands, David I F and Wilson, David C and Hansen, Richard and Chalmers, Iain},
  title = {Selecting High-Risk Patients With Pediatric Crohn’s Disease for Top-Down Anti-TNF as per the 2021 ECCO-ESPGHAN Guidelines: A 5-Year Nationwide Retrospective Analysis From Scotland (2016-2020)},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {8},
  pages = {2059--2065},
  doi = {10.1093/ibd/izae298}
}
Kostenlos starten →